Mosby's 2014 Nursing Drug Reference (42 page)

BOOK: Mosby's 2014 Nursing Drug Reference
12.45Mb size Format: txt, pdf, ePub
Do not confuse:

argatroban
/Aggrastat

ACTION:

Direct inhibitor of thrombin, it reversibly binds to thrombin active site

USES:

Anticoagulation prevention/treatment of thrombosis in heparin-induced thrombocytopenia; adjunct to percutaneous coronary intervention (PCI) in those with history of HIT

Unlabeled uses:
Acute MI, DIC, use in infants/children/adolescents

CONTRAINDICATIONS:

Hypersensitivity, overt major bleeding

Precautions:
Pregnancy (B), breastfeeding, children, intracranial bleeding, renal function impairment, hepatic disease, severe hypertension, after lumbar puncture, spinal anesthesia, major surgery, congenital/acquired bleeding, GI ulcers

DOSAGE AND ROUTES
Calculator
DVT, Pulmonary Embolism

• Adult: CONT IV INF
2 mcg/kg/min; adjust dose until steady-state aPTT is 1.5-
3× initial baseline, max 100 sec, max dose 10 mcg/kg/min

• Infant/child/adolescent (unlabeled):
CONT IV INF
0.75 mcg/kg/min, monitor aPTT q2hr until stable then at least daily

Hepatic dose

• Adult: CONT INF
0.5 mcg/kg/min, adjust rate based on aPTT

Percutaneous coronary intervention (PCI) in HIT

• Adult: IV INF
25 mcg/kg/min and bolus of 350 mcg/kg given over 3-5 min, check ACT 5-10 min after bolus completed, proceed if ACT >300 sec; if ACT <300 sec, give another 150 mcg/kg
BOL,
increase inf rate to 30 mcg/kg/min, recheck ACT in 5-10 min; if ACT >450 sec, decrease inf rate to 15 mcg/kg/min, recheck ACT in 5-10 min; when ACT is therapeutic, continue for duration of procedure

Acute MI (unlabeled)

• Adult: IV
loading dose of 1000 mcg/kg over 1 min, then 1-3 mcg/kg/min

DIC (unlabeled)

• Adult: CONT IV
0.7 mcg/kg/min

Available forms:

Inj 100 mg/ml (2.5 ml; must dilute 100-fold)

Administer:

• 
Avoid all IM inj that may cause bleeding

IV, direct route

• 
For PCI:
350 mg/kg bol and continuous inf of 25 mcg/kg/min; check ACT 5-10 min after bolus

Intermittent IV INF route

• 
Dilute
in 0.9% NaCl, D
5
, LR to a final conc of 1 mg/ml;
dilute
each 2.5-ml vial 100-fold by mixing with 250 ml of diluent, mix by repeated inversion of the diluent bag for 1 min; may briefly be slightly hazy

• 
Dosage adjustment may be made after review of aPTT, max 10 mcg/kg/min

SIDE EFFECTS

CNS:
Fever
,
intracranial bleeding,
headache

CV:
Atrial fibrillation, coronary thrombosis, MI, myocardial ischemia, coronary occlusion, ventricular tachycardia, bradycardia,
chest pain, hypotension

GI:
Nausea, vomiting, abdominal pain, diarrhea
,
GI bleeding

GU:
Hematuria,
abnormal kidney function, UTI

HEMA:
Hemorrhage

MISC:
Back pain, headache
, infection

RESP:
Pneumonia, dyspnea, coughing, hemoptysis

SYST:
Sepsis

PHARMACOKINETICS

Metabolized in liver by P450 CYP3A 4/5, distributed to extracellular fluid, 54% plasma protein binding, half-life 39-51 min, excreted in feces, steady state 1-3 hr

INTERACTIONS

Increase:
bleeding risk—antiplatelets, NSAIDs, salicylates, dipyridamole, clopidogrel, ticlopidine, heparin, warfarin, glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide), thrombolytics (alteplase, reteplase, urokinase, tenecteplase), other anticoagulants

NURSING CONSIDERATIONS
Assess:

• 
Baseline aPTT before treatment; do not start treatment if aPTT ratio is ≥2.5, then check aPTT 2 hr after initiation of treatment and at least daily thereafter

• 
aPTT, which should be 1.5-3 × control, draw blood for ACT every 20-30 min during long PCI

 
Bleeding
gums: petechiae; ecchymosis; black, tarry stools; hematuria/epistaxis; B/P; vaginal bleeding, possible hemorrhage

 
Anaphylaxis:
dyspnea, rash during treatment

• 
Fever, skin rash, urticaria

Evaluate:

• 
Therapeutic response: absence or decrease of thrombosis

Teach patient/family:

• 
To use a soft-bristle toothbrush to avoid bleeding gums; avoid contact sports; use electric razor; avoid IM inj

• 
To report any signs of bleeding: gums, under skin, urine, stools; trouble breathing wheezing, skin rash

• 
To notify prescriber if planning to become pregnant, breastfeeding

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

ARIPiprazole (Rx)

(a-rip-ip-pra′zol)

Abilify, Abilify Discmelt

Func. class.:
Antipsychotic

Chem. class.:
Quinolinone

ACTION:

Exact mechanism unknown; may be mediated through both DOPamine type 2 (D
2
, D
3
) and serotonin type 2 (5-HT
1A
, 5-HT
2A
) antagonism

USES:

Schizophrenia and bipolar disorder (adults and adolescents), agitation, mania, major depressive disorder, short-term mania or mixed episodes of bipolar disorder; irritability in patients with autism

Unlabeled uses:

Psychosis in patients with dementia

CONTRAINDICATIONS:

Breastfeeding, hypersensitivity, seizure disorders

Precautions:
Pregnancy (C), geriatric patients, renal/hepatic/cardiac disease

 

Black Box Warning:

Children, dementia, suicidal ideation

DOSAGE AND ROUTES
Calculator
Major depressive disorder

• Adult: PO
2-5 mg/day as an adjunct to other antidepressant treatment; adjust by 5 mg at ≥1 wk (range, 2-15 mg/day)

Schizophrenia

• Adult: PO
10-15 mg/day; if needed, dosage may be increased to 30 mg/day after 2 wk; maintenance 15 mg/day; periodically reassess

• Adolescent 13-17 yr: PO
2 mg/day, may increase to 5 mg after 2 days, then 10 mg after 2 more days, max 30 mg/day

Bipolar disorder

• Adult: PO
15 mg/day, may increase to 30 mg if needed (monotherapy); adjunctive to lithium or valproate PO 10-15 mg qd, may increase to 30 mg if needed

• Child >10 yr, adolescents: PO
2 mg, titrate to 5 mg/day after 2 days to target of 10 mg/day after another 2 days

Agitation with bipolar disorder/schizophrenia

• Adult: IM
9.75 mg as a single dose, may start with a lower dose, max 30 mg/day

Irritability associated with autism

• Child

6 yr, adolescents: PO
2 mg/day, increase to 5 mg/day after 1 wk, may increase to 10-15 mg/day if needed; dose changes should not occur more frequently than q1wk

Potential CYP2D6 inhibitor, strong CYP3A4 inhibitors

• Adult: PO
Reduce to 50% of usual dose, increase dose when CYP2D6, CYP3A4 inhibitor withdrawn

Combination of strong CYP3A4/CYP2D6 inhibitors

• Adult: PO
reduce to 25% of usual dose

Acute psychosis (unlabeled)

• Adults: PO
15 mg/day, may increase to 20-30 mg/day after 3 wk

Available forms:

Tabs 2, 5, 10, 15, 20, 30 mg; inj 9.75 mg/1.3 ml; orally disintegrating tab 10, 15 mg; oral sol 1 mg/ml

Administer:
PO route

• 
May be given without regard to meals

• 
Orally disintegrating tabs; do not open blister until ready to use, do not push tab through foil; place on tongue, allow to dissolve, swallow, do not divide

• 
Oral liquid: use calibrated measuring device

• 
Oral solution: can be substituted for tablet on a mg-per-mg, up to 25 mg dose. Patients receiving 30-mg tablets should receive 25 mg of solution

IM route

• 
Give IM only; inject slowly, deeply into muscle mass; discard unused portion

SIDE EFFECTS

CNS:
Drowsiness, insomnia, agitation, anxiety, headache
,
seizures, neuroleptic malignant syndrome,
light-headedness, akathisia, asthenia, tremor
,
stroke, suicidal ideation,
dystonia

CV:
Orthostatic hypotension,
tachycardia

EENT:
Blurred vision, rhinitis

GI:
Constipation, nausea, vomiting
, jaundice,
weight gain

Other books

The Exception by Sandi Lynn
Weekend Agreement by Barbara Wallace
Intimate Whispers by Dee Carney
Modern American Snipers by Chris Martin
The Years That Followed by Catherine Dunne
03 - Call to Arms by Mitchel Scanlon - (ebook by Undead)
His Clockwork Canary by Beth Ciotta
Stone Cold Surrender by Brenda Jackson